12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

Stopped early · Phase 2

Conditions studied: Macular Degeneration

In brief

The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.

Key facts

Study ID: NCT01362348
Run by: GlaxoSmithKline
People needed: 19
Starts: 2011-07-07
Expected to finish: 2012-04-16
Last updated by the study team: 2017-09-21

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subjects eligible for enrolment in the study must meet all of the following criteria:
Consent: Subject understands the procedures, agrees to participate in the study (including participation in the CFH Y402H pharmacogenetic research), and has signed and dated the informed consent form prior to the initiation of any study-related activities. If the subject is unable to read the consent form due to visual impairment then the consent must be read to the subject verbatim by the person administering the consent, a family member, or legally acceptable representative. (Note: Consent by legally acceptable representative is allowed where this is in accordance with local laws, regulations, and ethics committee policy.)
Age-related macular degeneration: For each subject enrolled in the study, only one eye (study eye) will be treated, and eligibility criteria apply to the study eye. All of the following characteristics are required and must be confirmed by the central reading center:
CNV caused by AMD that extends under the geometric center of the foveal avascular zone
Center subfield thickness (inclusive of subretinal fluid) > 320 microns on OCT [SPECTRALIS® (Heidelberg)]
Total lesion area ≤12 disc areas on fluorescein angiography, where the lesion complex includes CNV, blood, blocked florescence not from blood, and serous detachment of the retinal pigment epithelium
CNV comprises < 50% of lesion area
classic CNV comprises < 50% of the lesion area
fibrosis comprises ≤ 25% of lesion area
if no evidence of classic CNV, then presumed to have recent disease progression based on deterioration (≥ 5 letter decrease in vision or evidence of growth of a CNV lesion on fluorescein angiography ) within the last 3 months or evidence of hemorrhage from CNV
Visual acuity: Best-corrected visual acuity score by electronic ETDRS in the study eye of between 25 and 73 letters (approximately equivalent to Snellen VA of 20/320 to 20/32) at screening
Gender and age: Subject is a male or female adult 50 years of age or older.
Non-childbearing potential: Female subject is of non-childbearing potential defined as being physiologically incapable of becoming pregnant. This includes any female who is post-menopausal (12 months of spontaneous amenorrhea) or who is surgically post-menopausal (via documented hysterectomy or bilateral tubal ligation). In questionable cases of postmenopausal status, a blood sample with simultaneous follicle stimulating hormone (FSH) >40 MIU/mL and estradiol <40 pg/mL (<140 pmol/L) [or equivalent values based on local laboratory criteria] is confirmatory. Refer to the SPM for more information.
Study Compliance: Subject is able and willing to comply with the study requirements and is able and willing to attend all scheduled visits.
Liver function tests: Subject has liver chemistry values that are within normal limits or clinically insignificant as evidenced by serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2xULN; alkaline phosphatase and bilirubin <1.5xULN (isolated bilirubin >1.5xULN is acceptable, if bilirubin is fractionated and direct bilirubin is < 35%).
QT interval: Subject has a QTcF value < 450 msec, or < 480 msec for subjects with Bundle Branch Block. [Note: subjects with paced rhythms may be considered pending discussion with the medical monitor.]

You may not qualify if…

Subjects meeting any of the following criteria must not be enrolled in the study:
Study Eye:
Additional eye disease in the study eye that could compromise best-corrected visual acuity (e.g. glaucoma with documented visual field loss, clinically significant diabetic retinopathy, ischemic optic neuropathy, infection or retinitis pigmentosa)
CNV in the study eye due to other causes unrelated to age-related macular degeneration
Presence of retinal angiomatous proliferation (RAP) in the study eye, as determined by the investigator (confirmation by indocyanine green angiography is not required)
Geographic atrophy involving the center of the fovea in the study eye
Anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation of the fundus for photographs, fluorescein angiography and spectral-domain OCT
Vitreous, subretinal or retinal hemorrhage in the study eye that is unrelated to AMD
Presence of an RPE tear in the study eye
Aphakia or total absence of the posterior capsule (Yttrium aluminum garnet (YAG) capsulotomy permitted) in the study eye
History of vitrectomy in the study eye
Intraocular surgery in the study eye within 3 months prior to treatment
Any previous treatment in the study eye for neovascular AMD, approved or investigational
Fellow Eye:
Current intravitreal anti-VEGF therapy in the fellow eye
Best-corrected visual acuity score by electronic ETDRS < 56 letters in the fellow eye at screening
Concurrent Conditions or Concomitant Medications:
Subject has uncontrolled glaucoma (intraocular pressure > 25 mmHg) despite treatment with anti-glaucoma medication.
A known, positive test for Hepatitis B surface antigen or Hepatitis C antibody within 3 months of screening
Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
Active bleeding disorder or a history of hemoptysis, cerebral or clinically significant gastrointestinal hemorrhage within 6 months of screening
Significant uncontrolled or unstable cardiovascular, nervous system, pulmonary, renal, endocrine, or gastrointestinal disease for example:
Uncontrolled diabetes mellitus, with hemoglobin A1c (HbA1c) > 10%
Myocardial infarction or stroke within 6 months of screening
Major surgery within 3 months of screening

Where it is running

GSK Investigational Site — Phoenix, Arizona, United States
GSK Investigational Site — Miami, Florida, United States
GSK Investigational Site — Winter Haven, Florida, United States
GSK Investigational Site — Decatur, Georgia, United States
GSK Investigational Site — Boston, Massachusetts, United States
GSK Investigational Site — Grand Rapids, Michigan, United States
GSK Investigational Site — Cleveland, Ohio, United States
GSK Investigational Site — Austin, Texas, United States
GSK Investigational Site — Houston, Texas, United States
GSK Investigational Site — Paris, France
GSK Investigational Site — Paris, France
GSK Investigational Site — Munich, Bavaria, Germany
GSK Investigational Site — Bonn, North Rhine-Westphalia, Germany
GSK Investigational Site — Münster, North Rhine-Westphalia, Germany
GSK Investigational Site — Leipzig, Saxony, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.